FOLFIRI plus panitumumab as second-line treatment in mutated RAS metastatic colorectal cancer patients who converted to wild type RAS after receiving first-line FOLFOX/CAPOX plus bevacizumab-based treatment: Phase II CONVERTIX trial

Cancer Patients ◽

Phase Ii ◽

Treatment Phase ◽

Line Treatment ◽

Second Line ◽

Wild Type ◽

First Line ◽

Colorectal Cancer Patients

Faculty of 1000 evaluation for FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO).

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.718009648.793485773 ◽

2013 ◽

Author(s):

Yiqian Nancy You ◽

Craig Messick

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

Wild Type ◽

First Line ◽

FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO)

Annals of Oncology ◽

10.1093/annonc/mdt165 ◽

2013 ◽

Vol 24 (8) ◽

pp. 2062-2067 ◽

Cited By ~ 67

Author(s):

L. Fornaro ◽

S. Lonardi ◽

G. Masi ◽

F. Loupakis ◽

F. Bergamo ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

Wild Type ◽

First Line ◽

CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial

Cancer Communications ◽

10.1186/s40880-019-0374-8 ◽

2019 ◽

Vol 39 (1) ◽

pp. 28 ◽

Cited By ~ 1

Author(s):

Yuankai Shi ◽

Jin Li ◽

Jianming Xu ◽

Yan Sun ◽

Liwei Wang ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Phase Iii ◽

Line Treatment ◽

Second Line ◽

Wild Type ◽

Open Label ◽

Phase Iii Trial ◽

Colorectal Cancer Patients

Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study

British Journal of Cancer ◽

10.1038/sj.bjc.6603493 ◽

2007 ◽

Vol 96 (3) ◽

pp. 439-444 ◽

Cited By ~ 21

Author(s):

E Bajetta ◽

◽

M Di Bartolomeo ◽

R Buzzoni ◽

L Mariani ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

Intensive first line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: Preliminary phase II data and individual limiting toxicity syndromes prediction by pharmacogenomic biomarkers

Annals of Oncology ◽

10.1093/annonc/mdy151.205 ◽

2018 ◽

Vol 29 ◽

pp. v57 ◽

Cited By ~ 1

Author(s):

G. Bruera ◽

S. Massacese ◽

F. Pepe ◽

U. Malapelle ◽

A. Dal Mas ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Wild Type ◽

First Line ◽

Triplet Chemotherapy ◽

Preliminary Phase

Differential prognosis of metastatic colorectal cancer patients post-progression to first-line triplet chemotherapy plus bevacizumab, FIr-B/FOx, according to second-line treatment and KRAS genotype

International Journal of Oncology ◽

10.3892/ijo.2013.2179 ◽

2013 ◽

Vol 44 (1) ◽

pp. 17-26 ◽

Cited By ~ 6

Author(s):

GEMMA BRUERA ◽

KATIA CANNITA ◽

ALDO VICTOR GIORDANO ◽

ROBERTO VICENTINI ◽

CORRADO FICORELLA ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Line Treatment ◽

Second Line ◽

First Line ◽

Triplet Chemotherapy ◽

Triplet Chemotherapy Plus Bevacizumab

The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients

BMC Cancer ◽

10.1186/s12885-018-4001-x ◽

2018 ◽

Vol 18 (1) ◽

Cited By ~ 3

Author(s):

Francesca Battaglin ◽

Marta Schirripa ◽

Federica Buggin ◽

Filippo Pietrantonio ◽

Federica Morano ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽

Wild Type ◽

First Line ◽

Randomized Phase Ii ◽

Colorectal Cancer Patients

627 POSTER UFT/LV combined with oxaliplatin (TEGAFOX) or with irinotecan (TEGAFIRI) as first-line treatment for metastatic colorectal cancer patients (pts). results of a randomized phase II I.T.M.O. study

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(05)80923-1 ◽

2005 ◽

Vol 3 (2) ◽

pp. 177

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

Intensive first line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: Preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.e15517 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. e15517-e15517

Author(s):

Gemma Bruera ◽

Silvia Massacese ◽

Francesco Pepe ◽

Umberto Malapelle ◽

Antonella Dal Mas ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Wild Type ◽

First Line ◽

Triplet Chemotherapy ◽

Preliminary Phase

The best strategy for RAS wild-type metastatic colorectal cancer patients in first-line treatment: A classic and Bayesian meta-analysis

Critical Reviews in Oncology/Hematology ◽

10.1016/j.critrevonc.2018.03.003 ◽

2018 ◽

Vol 125 ◽

pp. 69-77 ◽

Cited By ~ 6

Author(s):

Domenico Ciliberto ◽

Nicoletta Staropoli ◽

Francesca Caglioti ◽

Silvia Chiellino ◽

Antonella Ierardi ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Meta Analysis ◽

Line Treatment ◽

Wild Type ◽

First Line ◽